Blar i forfatter "Fløisand, Yngvar"

Viser treff 1-4 av 4

    • Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. 

      Barratt-Due, Andreas; Fløisand, Yngvar; Lang, Hilde Elisabeth; Kvam, Ann Kristin; Holme, Pål Andre; Bergseth, Grete; Tjønnfjord, Geir Erland; Mollnes, Tom Eirik (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-04-22)
      Catastrophic antiphospholipid syndrome is associated with excessive complement activation explaining the clinical efficacy of complement inhibitory treatment.

    • Early response evaluation by single cell signaling profiling in acute myeloid leukemia 

      Tislevoll, Benedicte Sjo; Hellesøy, Monica; Fagerholt, Oda Helen Eck; Gullaksen, Stein-Erik; Srivastava, Aashish; Birkeland, Even; Kleftogiannis, Dimitrios; Ayuda Duran, Pilar; Piechaczyk, Laure Isabelle; Tadele, Dagim Shiferaw; Skavland, Jørn; Panagiotis, Baliakas; Hovland, Randi; Andresen, Vibeke; Seternes, Ole Morten; Tvedt, Tor Henrik Anderson; Aghaeepour, Nima; Gavasso, Sonia; Porkka, Kimmo; Jonassen, Inge; Fløisand, Yngvar; Enserink, Jorrit; Blaser, Nello; Gjertsen, Bjørn Tore (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-01-07)
      Aberrant pro-survival signaling is a hallmark of cancer cells, but the response to chemotherapy is poorly understood. In this study, we investigate the initial signaling response to standard induction chemotherapy in a cohort of 32 acute myeloid leukemia (AML) patients, using 36-dimensional mass cytometry. Through supervised and unsupervised machine learning approaches, we find that reduction of ...

    • Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome 

      Gustavsen, Alice; Skattum, Lillemor; Bergseth, Grete; Lorentzen, Bjørg; Fløisand, Yngvar; Bosnes, Vidar; Mollnes, Tom Eirik; Barratt-Due, Andreas (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-03-01)
      Rationale:Antiphospholipid syndrome (APS) in pregnancy may trigger the lifethreatening catastrophic antiphospholipid syndrome (CAPS). Complement activation is implicated in the pathogenesis, and inhibition of complement factor C5 is suggested as an additional treatment option.<p> Patient concerns, diagnosis and interventions: We present a pregnant patient treated with the C5-inhibitor eculizumab ...

    • A Nationwide Study of GATA2 Deficiency in Norway-the Majority of Patients Have Undergone Allo-HSCT 

      Jørgensen, Silje Fjellgård; Buechner, Jochen; Myhre, Anders E.; Galteland, Eivind; Spetalen, Signe; Kulseth, Mari Ann; Sorte, Hanne Sørmo; Holla, Øystein Lunde; Lundman, Emma; Alme, Charlotte; Heier, Ingvild; Flægstad, Trond; Fløisand, Yngvar; Benneche, Andreas; Fevang, Børre; Aukrust, Pål; Stray-Pedersen, Asbjørn; Gedde-Dahl, Tobias; Nordøy, Ingvild (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-12-10)
      Purpose: GATA2 deficiency is a rare primary immunodeficiency that has become increasingly recognized due to improved molecular diagnostics and clinical awareness. The only cure for GATA2 deficiency is allogeneic hematopoietic stem cell transplantation (allo-HSCT). The inconsistency of genotype-phenotype correlations makes the decision regarding "who and when" to transplant challenging. Despite ...